Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence
Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of alcohol use disorders. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact
of concurrent alcohol consumption at high levels, multiple physical comorbidities which may interfere with pharmacological effects, distribution and metabolism, and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles which need to
be balanced with the objective of treatment (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk- benefit profile in each case.
627-645
Sinclair, Julia
be3e54d5-c6da-4950-b0ba-3cb8cdcab13c
Baldwin, David
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Chambers, Sophia, Elaine
144bdaab-9a0e-41d9-b471-6abe343ce375
Shiles, C.J
06563301-0f7c-41c7-987c-462064159479
Sinclair, Julia
be3e54d5-c6da-4950-b0ba-3cb8cdcab13c
Baldwin, David
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Chambers, Sophia, Elaine
144bdaab-9a0e-41d9-b471-6abe343ce375
Shiles, C.J
06563301-0f7c-41c7-987c-462064159479
Sinclair, Julia, Baldwin, David, Chambers, Sophia, Elaine and Shiles, C.J
(2016)
Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Drug Safety, 39 (7), .
(doi:10.1007/s40264-016-0416-y).
Abstract
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of alcohol use disorders. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact
of concurrent alcohol consumption at high levels, multiple physical comorbidities which may interfere with pharmacological effects, distribution and metabolism, and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles which need to
be balanced with the objective of treatment (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk- benefit profile in each case.
Text
SAFETY AND TOLERABILITY OF PHARMACOLOGICAL TREATMENT OF ALCOHOL DEPENDENCE
More information
Submitted date: 15 February 2016
e-pub ahead of print date: 29 March 2016
Organisations:
Clinical & Experimental Sciences
Identifiers
Local EPrints ID: 411163
URI: http://eprints.soton.ac.uk/id/eprint/411163
ISSN: 0114-5916
PURE UUID: a1d998cb-4541-4364-b80e-6f012acb7c67
Catalogue record
Date deposited: 15 Jun 2017 16:31
Last modified: 16 Mar 2024 02:55
Export record
Altmetrics
Contributors
Author:
Sophia, Elaine Chambers
Author:
C.J Shiles
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
